[Clinical evaluation of Ftorafur (author's transl)].
The new soviet antimetabolite Ftorafur (N1-2'-Furanidyl-5-Fluorouracil, FFU) has been clinically evaluated in 18 selected patients with various solid tumours. Several of them had been treated before with other drugs. FFU was given to 8 patients as a monotherapy whereas 10 patients received the drug in combination with other therapeutic measures. A total response rate of 9/18 was seen. Three out of 8 patients treated with FFU alone have responded objectively. Due to its low toxicity FFU became a clinically interesting drug which is suitable for long-lasting administration. Its therapeutic activity is similar to that of 5-Fluorouracil. FFU is especially effective in carcinomas of the breast and the gastro-intestinal tract. It can be applied locally or safely be combined with other drugs or with irradiation.
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D001984:Bronchial Neoplasms / Q000188:drug therapy; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005663:Furans / Q000627:therapeutic use; D006801:Humans; D008479:Mediastinal Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D005663:Furans; D005472:Fluorouracil
Die klinische Erprobung von Ftorafur